| Literature DB >> 35279366 |
Barbara Siri1, Giorgia Olivieri2, Antonio Angeloni3, Sara Cairoli4, Claudia Carducci3, Giovanna Cotugno2, Silvia Di Michele5, Teresa Giovanniello3, Giancarlo La Marca6, Francesca Romana Lepri7, Antonio Novelli7, Claudia Rossi8, Michela Semeraro4, Carlo Dionisi-Vici2.
Abstract
Citrulline is a target analyte measured at expanded newborn screening (NBS) and its elevation represents a biomarker for distal urea cycle disorders and citrin deficiency. Altered ratios of citrulline with other urea cycle-related amino acids are helpful for the differential diagnosis. However, the use of cut-off values in screening programmes has raised the issue about the interpretation of mild elevation of citrulline levels detected at NBS, below the usual range observed in the "classical/severe" forms of distal urea cycle disorders and in citrin deficiency. Herein, we report ten subjects with positive NBS for a mild elevation of citrulline (<100 μmol/L), in whom molecular investigations revealed carriers status for argininosuccinate synthase deficiency, a milder form of argininosuccinate lyase deficiency and two other diseases, lysinuric protein intolerance and dihydrolipoamide dehydrogenase deficiency, not primarily affecting the urea cycle. To guide the diagnostic process, we have designed an algorithm for mild citrulline elevation (<100 μmol/L) at NBS, which expands the list of disorders to be included in the differential diagnosis.Entities:
Keywords: Citrulline; Dihydrolipoamide_dehydrogenase_deficiency; Expanded_Newborn_Screening; Lysinuric_Protein_Intolerance; Urea_Cycle_disorders
Mesh:
Substances:
Year: 2022 PMID: 35279366 DOI: 10.1016/j.ymgme.2022.02.008
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.797